Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.
Milton, GB
Atopix was founded in 2012 and is headquartered in Milton, GB
Report incorrect company information

Atopix Office Locations

Atopix has an office in Milton
Milton, GB (HQ)
Milton Park Innovation Centre 99 Park Dr
Show all (1)
Report incorrect company information

Atopix Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$5.1 m

Latest funding size

$5.07 m

Time since last funding

3 years ago


Atopix's latest funding round in July 2015 was reported to be $5.1 m. In total, Atopix has raised $5.1 m

Atopix Financials

Atopix's revenue was reported to be £316.01 k in FY, 2015 which is a 49.6% decrease from the previous period.

Net income (FY, 2016)

(3.4 m)

EBITDA (FY, 2016)

(3.3 m)

EBIT (FY, 2016)

(3.3 m)

Cash (4-Mar-2018)

431.3 k
GBPFY, 2013FY, 2014FY, 2015FY, 2016


225.3 k626.7 k316 k

Revenue growth, %


Operating expense total

2 m2.9 m4.8 m


(1.8 m)(2.3 m)(4.5 m)(3.3 m)
GBPFY, 2013FY, 2014FY, 2015FY, 2016


1.9 m2.5 m1.3 m431.3 k

Accounts Receivable

260 80

Current Assets

2.4 m3.1 m2.2 m783.2 k


64 64 6.3 k3 k
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(2.1 m)(2.5 m)(4.7 m)(3.4 m)

Cash From Operating Activities

(1.8 m)

Cash From Financing Activities

3.7 m

Net Change in Cash

1.9 m
GBPY, 2016

Financial Leverage

-0.3 x
Show all financial metrics
Report incorrect company information